BCM
DNTH icon

BlueCrest Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

BlueCrest Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,500
Closed -$410K – 440
2019
Q3 		$410K Hold
2,500
– – 0.03% 295
2019
Q2 		$590K Buy
2,500
+625
+33% +$155K 0.04% 202
2019
Q1 		$494K Buy
+1,875
New +$324K 0.02% 496

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlueCrest Capital Management's DNTH Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Dianthus Therapeutics (DNTH) in Q4 2019, closing a stake of 2,500 shares — an estimated $410K sold.

BlueCrest Capital Management first reported a position in DNTH in Q1 2019 and held it in 3 quarters. The position peaked at $590K in Q2 2019. 74 funds tracked by Wall St. Rank hold DNTH as of Q4 2019.

  • BlueCrest Capital Management reported no remaining Dianthus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 2,500 Dianthus Therapeutics shares in Q4 2019, an estimated $410K.
  • BlueCrest Capital Management first reported a position in Dianthus Therapeutics in Q1 2019 and held it in 3 quarters.
  • BlueCrest Capital Management's Dianthus Therapeutics position peaked at $590K in Q2 2019.
  • 74 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.